top of page

Penn Medicine's Dr. Donald O'Rourke describes advances being seen today in using CAR-T against glioblastoma

He says that intrathecal administration as well as taking a dual target approach are key factors that have led to improvements over previous attempts of using CAR-T against brain cancers.



Commentaires


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page